The Moderna Pop Is Real. The Moderna Price Tag Might Not Be.
(SeaPRwire) – By: Robert Kensington
Moderna’s stock is up 392% year-to-date. The average investor who watched this ticker sit in the doldrums for three years after the pandemic tail ended just flipped into euphoria overnight. That is the classic pattern I see in industrial biotech cycles. The data arrived. The market reacted violently. Now the real question is not whether the science works. The question is whether the price you pay today survives contact with reality. A $40 billion market cap injection in a single day for a single asset class sounds enormous. It also sounds like the market has already spent its future profits before the product has sold a single dose.
The Phase 3 trial for intismeran autogene met its primary endpoint. That matters. The combination of intismeran and Merck’s Keytruda kept melanoma patients cancer-free longer than Keytruda alone. The trial enrolled 1,100 participants. They received the injection after surgical removal of their melanomas. The vaccine targets up to 34 patient-specific neoantigens. Manufacturing takes about six weeks from sample collection to finished dose. During that window patients begin Keytruda. This is the first positive late-stage trial result for an mRNA cancer vaccine. Barclays raised its price target to $125 from $48. Wolfe Research upgraded from Underperform to Peer Perform. Wolfe projects unadjusted peak sales of $9.2 billion across four indications. Merck forecasts roughly $6 billion by 2035. Leerink Partners sees low-single-digit billions by 2032.
Here is what the press release does not tell you. That $9.2 billion is unadjusted. It gets split with Merck before anyone sees revenue on their own books. The nine ongoing trials in solid tumors have not reported. Lung cancer, kidney cancer, pancreas cancer. All of them are still open questions. Analysts view the melanoma data as encouraging for those pipelines. They are not the same thing. A treatment that works in melanoma does not automatically translate to every other solid tumor biology. The timeline matters too. 2027 is the projected commercialization year if interim data holds. That is three years away. Moderna’s 52-week high sits at $176.66. The stock was trading around $154.94 on Tuesday. With a $10 billion sales peak supporting roughly $40 billion in combined market value across Moderna and Merck, analysts are openly saying the upside is already priced in.
Moderna and Merck need each other for this deal to work at scale. Merck is desperate for the next blockbuster before Keytruda loses exclusivity. That gives Moderna leverage today. It also means Merck will control the commercial distribution channel. Profit splits go both ways. The supply chain for personalized mRNA manufacturing at six weeks per patient is not yet proven at commercial volume. Scaling from 1,100 trial participants to tens of thousands of real-world patients is an entirely different engineering problem. The next move will come from one of those nine ongoing trials. If one fails, the math changes. If one succeeds, the question becomes pricing. I would not chase this name at 392% YTD gains. Wait for the next data point. The market will hand you a better entry when the next trial result lands.
Author bio: Robert Kensington, an overseas entrepreneurial veteran with decades of experience in real-economy industrial investment, pharmaceutical commercialization strategy, and cross-sector capital allocation.